Advertisement

Topics

Sunovion Announces FDA Acceptance for Review of Supplemental New Drug Application for Latuda® ...

03:06 EDT 30 Jun 2017 | BioMedReports - Blog

Application seeks to expand LATUDA label to include treatment of depressive symptoms associated with bipolar I disorder in children and adolescents (10 to 17 years of age) –

Read more...

Original Article: Sunovion Announces FDA Acceptance for Review of Supplemental New Drug Application for Latuda® ...

NEXT ARTICLE

More From BioPortfolio on "Sunovion Announces FDA Acceptance for Review of Supplemental New Drug Application for Latuda® ..."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bipolar Disorders
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Over half of Bipolar cases develops before the age of 25. Bipolar ...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...